Table 3.

Some marine anti-cancerous compounds and their molecular targets

S. No.	Molecular targets		Name of the Drugs	References
	Microtubules		Dolastatin-10 (linear pentapeptide), diazonamide A (peptide), scleritodermin A (peptide), Vitilevuamide (bicyclic 13 amino acid peptide), Spongistatins (macrocyclic lactones), Taltobulin (HTI-286, tripeptide), Peloruside A (macrolide polyketide), Zampanolide (macrolide), Dictyostatin (macrolide polyketide), Discodermolide (polyketide), Laulimalide (macrolide).	[15, 124]
	Apoptosis & Autophagy		Nortopsentins A, B & C (imidazolediylbis [indole] alkaloids), Ilimaquinone (sesquiterpene quinone), Frondoside A (glycosylated triterpene), Stelletin A (triterpenoid), Echinoside A (sulfonylated holostane tetrasaccharide) and ds-echinoside A (a non-sulfated triterpene glycoside), makaluvamines (pyrroloiminoquinone alkaloids), Tyrindoleninone & 6-bromoisatin (indole derivatives), Monanchocidin A (guanidine alkaloid), didemnin B, CS5931(Polypeptide), Dolastatin 10, 15 and bryostatin 1 (Polyketides), Jasplakinolide (depsipeptide).	[15, 121–131]
1.1.1.1.	Kinase inhibitors	a. PKC (Protein Kinase-C)	11-hydroxystaurosporine, bryostatin-1, xestocyclamine A, (Z)-Axinohydantoin and debromo-Z-axinohydantoin, hymenialdisine and debromohymenialdisine, frondosins, BRS1, nakijiquinones, spongianolides, lasonolide A, penazetidine A, corallidictyals A and B.	[132–141]
		b. Cyclin Dependent Kinases	(a) Cyclin Dependent Kinase-1 inhibiting marine compounds: Hymenialdisine, Microxine, Variolin B. (b) Cyclin Dependent Kinase-4 inhibiting marine compounds: fascaplysin, Konbu’acidin A, halistanol sulfate.	[133]
		c. Tyrosine Protein Kinase (TPK)	Penta-, hexa- and hepta-prenylhydroquinone 4-sulfates, halenaquinone, halenaquinol, halenaquinol sulfate and xestoquinone, Melemeleone, 14-methoxyhalenaquinone and xestoquinolide.	[133]
		d. Epidermal Growth Factor Receptor	Tauroacidins A and B, Ma’edamine A, Spongiacidins A and B, (+)-aeroplysinin-1, 3,9-dimethyldibenzo [b,d]furan-1,7-diol, 3-(hydroxymethyl)-9-methyldibenzo[b,d]furan-1,7-diol, 1,7-dihydroxy-9-methyldibenzo [b,d] furan-3-carboxylic acid, 3′-norspongiolactone, gracilins, tetrahydroaplysulphurin-1.	[133]
		e. Mitogen-Activated Protein Kinase	Hymenialdisine and debromohymenialdisine, Liphagal 1, Dolastatin, Kahalalide F, Elisidepsin trifluoroacetate, Aplidine (dehydrodidemnin B, DDB, Aplidin), onnamide A and theopederin B.	[133]
	Angiogenesis, Invasion or Metastasis Inhibitors		Geodiamolide H, Stylissamide X, Suberreamoline A, Cortistatin A, Aeroplysinin-1, Motuporamines A, B and C, Bastadin 6, 9 & 16, Phidianidine A, Sceptrin, Latrunculins A and B, Laulimalide, ds-echinoside A, holothurin A and 24-dehydroechinoside A, frondoside A, perhydrobenzoxepine (A & B) and bicyclodecane (C & D), frondoside A, sipholenone A and sipholenol A & E and sipholenone A, Globostellatic acid X, Heteronemin, pachycladins A and D, Sarcophines, inulodurins A and B, Strongylophorine-26, Smenospongine, WA-25, Psammaplin A, Microsporins A and B, Azumamides A–E, Largazole.	[15, 142–149]
	Hypoxia Inducible Factor (HIF) Inhibitors		Laurenditerpenol, Furospongolide, Benzo[g]chromen-4-one and Benzo[h]chromen-4-one, Manassantin B, 7-hydroxyneolamellarin A.	[150–152]
	Topoisomerase Inhibitor		Makaluvamine A, Ascididemin, Lamellarin D.	[153, 154]
	Wnt Inhibitor		Gliotoxin, Fucoidan, cholestane-type steroids, ilimaquinone and ethylsmenoquinone	[97, 106, 113, 114]